PURPOSE: Romiplostim is a novel thrombopoiesis-stimulating peptibody that targets the thrombopoietin c-Mpl receptor, resulting in increased platelet production. The pharmacodynamic-mediated disposition (PDMDD) and its stimulatory effect on platelet production in Sprague-Dawley rats, rhesus monkeys, and cynomolgus monkeys following IV bolus and SC administration at various dose levels were determined. METHODS: The pharmacokinetic (PK) profile was described by a PDMDD model that accounts for romiplostim binding to the c-Mpl receptor. The PD model contained a series of aging compartments for precursor cells in bone marrow and platelets. The stimulatory function was described by an on-and-off function operating on the fractional receptor occupancy (RO). The threshold effect, RO(thr), and K(D) parameters were determinants of drug potency, whereas S(max) reflected drug efficacy. RESULTS: The model implicated that receptor-mediated clearance was negligible. RO(thr) estimated occupancies were 0.288, 0.385, 0.771 for rats, rhesus, and cynomolgus monkeys, respectively. The analogous estimated values of K(D) were 4.05, 2320, and 429 ng/mL, implying that romiplostim was much more potent in rats, which was confirmed by a dose-response (ratio of peak platelet count to baseline) relationship. CONCLUSIONS: The model adequately described romiplostim serum concentrations and platelet counts in rats, rhesus monkeys, and cynomolgus monkeys, and quantified linear clearance, PDMDD, and potency of romiplostim.
PURPOSE: Romiplostim is a novel thrombopoiesis-stimulating peptibody that targets the thrombopoietin c-Mpl receptor, resulting in increased platelet production. The pharmacodynamic-mediated disposition (PDMDD) and its stimulatory effect on platelet production in Sprague-Dawley rats, rhesus monkeys, and cynomolgus monkeys following IV bolus and SC administration at various dose levels were determined. METHODS: The pharmacokinetic (PK) profile was described by a PDMDD model that accounts for romiplostim binding to the c-Mpl receptor. The PD model contained a series of aging compartments for precursor cells in bone marrow and platelets. The stimulatory function was described by an on-and-off function operating on the fractional receptor occupancy (RO). The threshold effect, RO(thr), and K(D) parameters were determinants of drug potency, whereas S(max) reflected drug efficacy. RESULTS: The model implicated that receptor-mediated clearance was negligible. RO(thr) estimated occupancies were 0.288, 0.385, 0.771 for rats, rhesus, and cynomolgus monkeys, respectively. The analogous estimated values of K(D) were 4.05, 2320, and 429 ng/mL, implying that romiplostim was much more potent in rats, which was confirmed by a dose-response (ratio of peak platelet count to baseline) relationship. CONCLUSIONS: The model adequately described romiplostim serum concentrations and platelet counts in rats, rhesus monkeys, and cynomolgus monkeys, and quantified linear clearance, PDMDD, and potency of romiplostim.
Authors: James B Bussel; David J Kuter; James N George; Robert McMillan; Louis M Aledort; George T Conklin; Alan E Lichtin; Roger M Lyons; Jorge Nieva; Jeffrey S Wasser; Israel Wiznitzer; Reggie Kelly; Chien-Feng Chen; Janet L Nichol Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp Journal: J Pharmacokinet Pharmacodyn Date: 2014-08-21 Impact factor: 2.745
Authors: Wojciech Krzyzanski; John M Harrold; Liviawati S Wu; Juan Jose Perez-Ruixo Journal: J Pharmacokinet Pharmacodyn Date: 2016-09-09 Impact factor: 2.745
Authors: Merriline M Satyamitra; Andrea L DiCarlo; Brynn A Hollingsworth; Thomas A Winters; Lanyn P Taliaferro Journal: Radiat Res Date: 2022-05-01 Impact factor: 3.372
Authors: James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple Journal: Drug Des Devel Ther Date: 2021-05-26 Impact factor: 4.162